Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
28 sept. 2023 06h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
01 sept. 2023 17h57 HE
|
Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
21 juil. 2023 02h15 HE
|
Turnstone Biologics Corp.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
08 avr. 2022 13h02 HE
|
Nurix Therapeutics, Inc.
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal...
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
12 nov. 2021 07h09 HE
|
Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
12 nov. 2021 07h07 HE
|
Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
T-Cell Therapy Market To Reach USD 8.37 Billion By 2027 | Reports and Data
19 févr. 2020 14h00 HE
|
Reports and Data
New York, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The Global T-Cell Therapy Market is forecast to reach USD 8.37 Billion by 2027, according to a new report by Reports and Data. The T-cell therapy involves...